Complementary and alternative medicine market expected to generate $196.87 billion globally by 2025



Not for distribution in the U.S. or to U.S. Newswire Services

VANCOUVER, British Columbia, June 20, 2018 (GLOBE NEWSWIRE) -- BlissCo Cannabis Corp. (CSE:BLIS) (FRA:GQ4B), (“BlissCo”) is pleased to announce that Dr. Bryn Hyndman, former medical director of Qi Integrated Health, is joining BlissCo’s advisory board.

Dr. Hyndman is a board-certified medical doctor with the Canadian College of Family Physicians (CCFP) and a naturopath.

“We are focused on building a strong ecosystem that includes partners such as Dr. Hyndman to enable us to establish the BlissCo brand as a premium craft cannabis product in the medical market and recreational market when it is legal,” said Damian Kettlewell, CEO of BlissCo Cannabis Corp.

A report by Grand View Research estimates that the complementary and alternative medicine market is expected to generate $196.87 billion in revenue globally by 2025.

“There is a gap in modern medicine; doctors are trained in chronic disease management and acute emergencies. Science has, until now, relied on double-blind, placebo-controlled trials where single drugs are studied in isolation, but there are a wide range of medical compounds in cannabis and they work synergistically. You can’t break down a plant and isolate these ingredients because you will lose its essence,” said Hyndman.

BlissCo’s cannabis extraction lab with the first Midas MIDAS XII Co2 extraction system in Canada will ensure that BlissCo safely extracts therapeutic cannabis terpenes along with the whole plant oils, offering a full spectrum of benefits to patients.

“We are excited to work with Dr. Hyndman to ensure that our patient care model and medical cannabis products are aligned. As well, BlissCo is pursuing clinical trial research partners and Dr. Hyndman’s experience with medical cannabis will assist us with the design and roll out of our first clinical trial,” said Kettlewell.

About BlissCo Cannabis Corp.

BlissCo Cannabis Corp. (CSE: BLIS) (FRA: GQ4B) owns, through its wholly-owned subsidiary BlissCo Holdings Ltd., a license to produce marijuana under the Access to Cannabis for Medical Purposes Regulations (ACMPR) which was originally granted on March 29, 2018.

BlissCo began growing medical cannabis in early May 2018 and applied to Health Canada to amend its ACMPR license to include cannabis oil production in early June 2018.

BlissCo is projected to have a sales license inspection from Health Canada in August 2018 and earn a sales license in late September or early October 2018 to sell dried cannabis.

BlissCo's value proposition is to be a brand focused high-volume distributor, processor and packager of medical cannabis and adult use cannabis when it is legal in Canada.

BlissCo will be processing and distributing cannabis purchased from multiple supply agreements and from cannabis grown at its own state of the art facility in Metro Vancouver, B.C. Currently, BlissCo has a two-year supply agreement with The Supreme Cannabis Company Inc (TSX.V:FIRE) to purchase 3,000 kilograms of premium whole dried cannabis flower.

BlissCo is currently exploring brand expansion opportunities in multiple international markets where medical cannabis is federally legal.

Management is focused on establishing BlissCo as an iconic Canadian cannabis brand.

On Behalf of the Board of Directors

BLISSCO CANNABIS CORP.

Damian Kettlewell, CEO, Founder & Chair

For further information please contact:

Damian Kettlewell, CEO

(604) 484 9119, ext. 3

damian.kettlewell@blissco.com

Cautionary Statement

This news release contains certain forward-looking information and forward-looking statements within the meaning of applicable securities legislation (collectively “forward-looking statements”). The use of any of the word “will” and similar expressions are intended to identify forward-looking statements. These statements involve known and unknown risks, uncertainties and other factors that may cause actual results or events to differ materially from those anticipated in such forward-looking statements. Such forward-looking statements should not be unduly relied upon. This news release contains forward-looking statements and assumptions pertaining to the following: the ability to execute on our strategic plans and the impact on our future operations, capital expenditures, receipt of a cannabis oil license and a license to sell dried cannabis and other objectives. Actual results achieved may vary from the information provided herein as a result of numerous known and unknown risks and uncertainties and other factors. The Company believes the expectations reflected in those forward-looking statements are reasonable, but no assurance can be given that these expectations will prove to be correct. The Company does not undertake to update these forward-looking statements, except as required by law.

The CSE has in no way passed upon the merits of the proposed transaction and has neither approved nor disapproved the contents of this press release.



